“We are excited to introduce the unique Crunch experience to the residents of Plano and the neighboring communities,” said Tony Scrimale, CEO of CR Fitness. “We can’t wait to showcase how we combine top-tier equipment, exceptional classes, and personal training at an unbeatable value.”
Fusing fitness with entertainment, Crunch Plano boasts top-quality strength training equipment, an extensive selection of premier cardio equipment, a Group Fitness Studio, HIITZone™, a Cycling Studio, Cryotherapy, Dry Saunas, HydroMassage®, tanning facilities, and spacious locker rooms, among other amenities.
CR Fitness Holdings is led by a group of seasoned fitness industry veterans: Vince Julian, Geoff Dyer, Jeff Dotson, and Tony Scrimale, whose collective expertise surpasses 150 years. At present, the CR Fitness team operates 55 Crunch Fitness locations, covering regions in Florida, Georgia, North Carolina, and Texas. The forthcoming debut of Crunch Plano as the 56th location marks another milestone in their expansion across Texas, complementing CR Fitness’ existing Crunch locations in Frisco and Arlington. Additionally, they have announced the upcoming openings of Crunch Allen and Crunch North Richland Hills, formerly UFC gyms, both set to open their doors in late December, further solidifying their presence in the State of Texas.
To kickstart the festivities and provide our community with a preview of what awaits, Crunch Plano will host a “Sneak Peek Sip Sip” event on Thursday, October 12, from 6 p.m. to 9 p.m. Everyone is invited to join in the festivities and embark on their journey towards a healthier, happier lifestyle.
Applications for Laser Research ZnSe Plano-Convex Lenses include industrial inspection and measurement equipment, medical diagnostics devices, laser beam expanding, collimation systems, Lidar systems, remote sensing and surveillance, infrared imaging and spectroscopy, and scientific research including astronomy and space observation.
Laser Research ZnSe Plano-Convex Lenses are priced according to size and quantity. Price quotations are available and delivery is from stock.
For more information contact:
Laser Research Optics A Division of Meller Optics, Inc. Scott Rouillard, Sales Mgr. 120 Corliss St. Providence, RI 02904 (888) 239-5545 FAX (401) 331-4004 e-mail: [email protected] http://www.laserresearch.net
Certification Enables Canopy Growth to Continue Exporting High Quality Cannabis to Global Medical Markets SMITHS FALLS, ON, Oct. 10, 2023 /PRNewswire/ – Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) announced today that it received EU GMP…
This unique, encyclopedic resource analyzes the crucial healthcare trends that will affect wholesale distribution of prescription pharmaceuticals. Now in its 14th edition, The 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors offers 163 proprietary charts, exhibits, and data tables. It remains the most comprehensive resource for analyzing the pharmaceutical distribution industry’s economics, market structure, growth rates, forces of change, and interactions within the U.S. healthcare system. The new report also provides an updated analysis of each of the Big Three public companies’ business segments and underlying profitability, based upon DCI’s proprietary economic models.
“Biosimilars of provider-administered specialty drugs are now an important source of profits for wholesalers and specialty distributors,” Fein adds. “The biosimilar market has continued to expand as adoption grows, prices decline, and payers relax formulary limits.”
Dwellr is an online marketplace that directly connects families with the best senior communities tailored to the needs of their loved ones. LINCOLN, Neb., Oct. 10, 2023 /PRNewswire/ — Dwellr, a Nebraska-based startup, has secured $500,000 in funding, led by Move Venture Capital and…
AGH interventional cardiologists implanted their first AccuCinch device in July as part of the global clinical trial, formally named the CORCINCH-HF study. The device aims to reduce the size of the heart’s left ventricle, improving the heart’s strength and blood-pumping function and mitigating heart failure symptoms.
“The AccuCinch device is an exciting advancement in the management of progressive heart failure, as it’s designed to improve heart function with a minimally invasive approach,” said Dr. Kanwar. “It’s our hope that its efficacy will result in our patients living fuller lives, with reduced cardiovascular symptoms and even a possible increase in life expectancy.”
Roughly 5.7 million Americans are living with heart failure, and the number continues to grow across the country and here in western Pennsylvania as the population ages.
Heart failure patients suffer from debilitating symptoms including persistent exhaustion, trouble breathing, swelling, confusion and loss of memory.
About half of all heart failure patients have an enlarged left ventricle, which is often caused by the heart overworking to adequately pump blood throughout the body. The left ventricle is the main pumping chamber, and when it becomes enlarged it causes more stress on the heart, leading to a reduced “ejection fraction” (the amount of blood that your heart pumps each time it beats).
During the AccuCinch procedure, a flexible implant is attached to the interior of the left ventricular wall and then cinched. The implant is intended to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall, which in turn aims to minimize debilitating, progressive symptoms caused by heart failure.
“During this procedure, interventional cardiologists thread a catheter through the patient’s leg and track it into the left ventricle of the heart,” explained Dr. Kanwar. “When the cable is cinched, it acts like the string of a drawstring bag. Since it is a minimally invasive approach, we anticipate patients will be discharged the following day, getting them back to their daily routine quickly.”
AccuCinch is a viable option when existing therapies like lifestyle changes, medications and pacemakers are no longer able to manage the symptoms of heart failure. Early clinical data suggests the AccuCinch System may benefit patients who have heart failure with reduced ejection fraction, providing a new option that improves heart structure and function, and general quality of life.
“As a recognized leader in the treatment and management of progressive heart failure, AGH remains committed to participating in innovative clinical trials and research initiatives that help to shape the future of cardiovascular medicine,” said Stephen Bailey, MD, cardiothoracic surgeon and Chair of AHN Cardiovascular Institute. “Today’s announcement is a testament to our longstanding legacy of transforming cardiovascular care not only for patients throughout the region, but around the world.”
The CORCINCH-HF Study includes roughly 80 heart centers from around the world, including AGH. The study will enroll 400 patients and is being conducted to support a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA). Enrolled patients will be randomized to receive treatment with the AccuCinch System and guideline-directed medical therapy, or guideline-directed medical therapy alone.
For more information about this clinical study, and to find out if you might be a candidate for enrollment, please contact 412-359-6181.
About the Allegheny Health Network: Allegheny Health Network (AHN.org) is an integrated healthcare delivery system serving the greater Western Pennsylvania region. The Network is composed of 14 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, an employed physician organization, home and community-based health services, a research institute, and a group purchasing organization. The Network provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, trauma care, cardiovascular disease, organ transplantation, cancer care, orthopedic surgery, neurology and neurosurgery, women’s health, diabetes, autoimmune disease and more. AHN employs approximately 21,000 people, has more than 2,600 physicians on its medical staff and serves as a clinical campus for Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.
About The CORCINCH-HF Study and the AccuCinch System Enrolled patients will be randomized to receive treatment with the AccuCinch System plus guideline-direction medical therapy or guideline-directed medical therapy alone. To be eligible, patients must meet the following main criteria:
Have been told they have heart failure by their doctor
Have had their doctor explain that they have reduced ejection fraction (low heart pumping ability)
Are taking heart failure medications, but have symptoms that are worsening (e.g., shortness of breath, fatigue, coughing, leg swelling, or trouble breathing at night)
The AccuCinch System is an investigational device, which is currently being studied in the CORCINCH-HF pivotal trial, a prospective, randomized, open-label, multicenter, international, clinical safety and efficacy investigation (ClinicalTrials.gov Identifier: NCT04331769). Early clinical data suggests that the system may provide an effective treatment option by filling the gap between medication or cardiac resynchronization therapy and left ventricular assist devices (LVADs) or a heart transplant. The AccuCinch System was developed by Santa Clara, California-based Ancora Heart. Additional information is available at http://www.ancoraheart.com.
Trial met its primary endpoint showing NB-001 is safe and well-tolerated; efficacy measures support progression to registrational trial
MOUNTAIN VIEW, Calif., AND PHILADELPHIA, Oct. 10, 2023 /PRNewswire-PRWeb/ — Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover advanced therapeutics, announced topline data from a Phase 2 clinical trial of NB-001 (fasoracetam), a treatment for the neuropsychiatric symptoms associated with 22q11.2 deletion syndrome (“22q11DS”) in children. The data in the late-breaking abstract and poster presentation “A Randomized Double-Blind Placebo-Controlled Phase 2 Clinical Trial of NB-001 (Fasoracetam) for Neuropsychiatric Symptoms in Children with 22q11.2 Deletion Syndrome” were presented at the 52nd Child Neurology Society (CNS) Annual Meeting in Vancouver, BC, on October 5, 2023.
The trial included participants aged 6 to 17 years old with molecularly confirmed 22q11DS and a Clinical Global Impression (CGI)-Severity Scale score of ≥ 4 at screening. The patients also had either (1) psychiatric symptoms in the clinical range for anxiety disorder, attention deficit hyperactivity disorder (ADHD), or autism spectrum disorder, or (2) psychiatric symptoms in the subclinical range for at least 2 out of 3 of these neuropsychiatric disorders. The presence of a history of psychosis was an exclusion criterion for this trial.
Results from the multi-center, randomized, placebo-controlled crossover trial demonstrate the safety and tolerability of NB-001, as well as robust efficacy trends that further support evaluation in a registrational clinical trial.
“We are encouraged by the progress of NB-001 and its potential to help children who have 22q11DS,” said Neil Inala, President and CEO of Nobias Therapeutics. “The data further increase our confidence in our NB-001 program, particularly given the small sample size and limited treatment period of this trial. These findings also underscore the value of the genomic dataset and associated electronic health record (EHR) data around which we are building our AI-based deep phenotyping drug discovery engine.”
In this crossover trial, patients with 22q11DS received two 6-week treatment periods separated by a 1-week washout period. Each patient was randomly assigned to one of two treatment sequences: NB-001 followed by placebo or placebo followed by NB-001. Evidence from prior studies shows that one mechanistic effect of NB-001 is non-stimulant activation of multiple metabotropic glutamate receptors (mGluRs).
The primary endpoint of the trial was to determine the safety and tolerability of NB-001. The most common adverse events in the 37 patients treated were fatigue and nasopharyngitis in 9 percent of participants, while 6 percent experienced epistaxis, pyrexia, and/or vomiting. All adverse events were graded mild to moderate and there were no serious adverse events attributable to treatment.
The trial’s key secondary endpoint was to assess the efficacy of NB-001 using the CGI-Improvement Scale (CGI-I). The least squares mean CGI-I for the treatment period was 3.34 (standard error: 0.15) versus 3.69 (0.15) for placebo (delta=-0.36 (0.20), p=0.07). Investigators further found that NB-001 treatment resulted in improved CGI-I scores for all three symptom groups (ADHD, anxiety, and autism) as compared to their individual baseline scores. Proportionally, the number of patients responding to treatment was 1.4 to 1.7 times higher as compared with placebo. The trial was intended to be signal-finding and therefore was not powered for efficacy endpoint statistical significance.
“Many children with 22q11DS have symptoms of inattention, anxiety, and difficulties with social communication, and very often have symptoms in more than one of these domains. This constellation of symptoms often results in significant functional impairment. The results of this important trial demonstrate that NB-001 holds promise for the high unmet medical need in this patient group and support further clinical development of NB-001 in a registrational-intent Phase 3 clinical trial,” said Dr. Bridget Martell, M.D., Advising CMO for Nobias Therapeutics.
About 22q11DS 22q11.2 deletion syndrome (“22q11DS”), also known as DiGeorge syndrome, velocardiofacial syndrome (VCFS), conotruncal anomaly face syndrome, Takao syndrome, and Shprintzen syndrome, is the most common human deletion syndrome and is associated with delayed or incomplete development of several body structures or systems. The syndrome is also strongly associated with neuropsychiatric conditions, including attention deficit hyperactivity disorder (ADHD), anxiety, autism, and schizophrenia/psychosis.
About Nobias Therapeutics Nobias Therapeutics is a biotechnology company pioneering deep phenotyping to discover advanced therapeutics. Nobias uses its cutting-edge, applied AI platform to distill disease drivers and optimal points for therapeutic intervention from rich clinical and genetic datasets, and to accelerate the development of novel therapies for a broad range of disorders. To learn more, please visit http://www.nobiastx.com and follow Nobias Therapeutics on LinkedIn.
Extend has been designed to help businesses maintain momentum and value realization from their ServiceNow investment while reducing the reliance on hands-on day-to-day administration and development.
“Through years of experience in the ServiceNow ecosystem, we’ve developed Extend as an answer to the common challenges found in managing complex ServiceNow environments,” said Terry Pritchard, SVP of Portfolio Management at Crossfuze. “Challenges such as sourcing and retaining talent internally, staying on top of a growing backlog, and ensuring value is realized on a sustainable, ongoing basis are all addressed with the Extend model.”
The model has already been praised by early adopters for its efficient handling of resources and a significant decrease in management overhead. Combined with Crossfuze’s formidable expertise in ServiceNow, Extend has already shown the potential to greatly improve customer satisfaction, service delivery and overall value realization of the ServiceNow investment.
For more insight into how the Extend model reshapes the ServiceNow development landscape, visit www.crossfuze.com/extend.
About Crossfuze Crossfuze is an industry-leading ServiceNow Elite partner, known for its innovative end-to-end ServiceNow solutions. Dedicated to providing a seamless ServiceNow experience to its clients, Crossfuze boasts a robust portfolio of successful implementations across varied industries worldwide.
PatientClick, a leading provider of innovative healthcare solutions, is thrilled to announce the launch of its cutting-edge AI powered Depression Screening App, designed exclusively for mental health practices.
SAN DIEGO, Oct. 10, 2023 /PRNewswire-PRWeb/ — PatientClick, a leading provider of innovative healthcare solutions, is thrilled to announce the launch of its cutting-edge AI powered Depression Screening App, designed exclusively for mental health practices. This groundbreaking application is poised to revolutionize mental healthcare by providing advanced trending and deep analysis tools to healthcare providers. PatientClick’s Depression Screening App offers unparalleled insights into patient progress, enabling therapists to optimize therapy and treatment plans effectively.
PatientClick’s Depression Screening App is an invitation-only platform, integrating seamlessly with physicians’ Electronic Health Records (EHR) and Practice Management systems. By employing artificial intelligence, the app not only facilitates comprehensive patient screening but also offers detailed analysis of therapy outcomes. Mental health practitioners can now make data-driven decisions, enhancing the quality of care they provide to their patients.
One of the unique features of the app is its ability to assist psychiatrists with Transcranial Magnetic Stimulation (TMS) facility. Through early detection enabled by the Depression Screening App, psychiatrists can identify patients who could benefit from TMS treatment within the clinic. This early intervention enhances the chances of successful treatment outcomes, offering patients a more efficient and targeted approach to managing depression.
Additionally, PatientClick’s Depression Screening App is integrated with a robust Revenue Cycle Management system. This integration ensures that mental health practices no longer have to struggle for cash flow, allowing practitioners to focus on what matters most – providing uninterrupted therapy sessions and medical management. By streamlining administrative processes, PatientClick’s app allows practitioners to maintain a consistent and positive therapeutic environment, leading to higher patient satisfaction.
“We are excited to introduce our state-of-the-art Depression Screening App to mental health practices,” said Mr. Mehta, Co-Founder at PatientClick. “By leveraging artificial intelligence, we are empowering healthcare providers with valuable insights and tools to enhance patient outcomes significantly. This app not only simplifies the screening process but also provides in-depth analysis, enabling personalized treatment plans and improving the overall quality of mental healthcare.”
PatientClick’s Depression Screening App is now available to a select group of mental health practices through invitation only. To learn more about this innovative solution and how it can transform your practice, please visit www.patientclick.com or contact Scott Wilson at [email protected] or 877-901-9990.
About PatientClick: PatientClick, Inc offers electronic health records, practice management, revenue cycle management solutions. It offers the Artificial Intelligence engine for practice automation and workflow customization. Its patient centric approach offers solutions for value based care, CCM, RPM, mobile integrated healthcare solutions and interoperability. PatientClick EHR offers secured patient data Xchange with Telemedicine or Telehealth technology; our professional technology and healthcare engineering services offers custom workflow development which are web and mobile device compatible apps. To learn more about our KPI analytics solutions and patient engagement tools please visit www.patientclick.com or schedule a quick presentation by calling 1-877-901-9990.
The key to preventing yo-yo self-esteem is to separate grades from a child’s identity.
The shift for parents is to think and talk about grades as feedback.
Feedback is simply a result based on an action that was taken – in school, it’s a measure of how well they learned the material.
Grades don’t mean that a child is “smart” or “dumb”, “good” or “bad”. Grades simply mean a child has either learned what they needed to know and did the work they needed to do, or they didn’t.
When children learn to interpret grades as feedback, and separate grades from “who they are”, it empowers them to deal with any grade, without impacting their self-esteem.
For example, what could parents say about an “A” report card?
Instead of saying something like, “You’re so smart” or “You’re an ‘A-student!” Parents could say, “Wow – you made a great grade. Looks like you really learned the material.”
The first comment labels the child whereas the second comment is objective feedback on the child’s work.
What could parents say about a C, D, or F grade?
A parent can say something like, “It doesn’t look like you learned the material that you needed to know. Let’s put together a plan to make sure you are prepared going forward, otherwise you may fall behind and future tests will be even more difficult.”
This approach tackles the low grade as a problem to be solved versus labeling the child.”
Renaye adds, “When grown-ups talk with kids about grades, it’s important to remember to take an objective stance – focus on the results versus judging the child.”
Using grades as feedback is effective for homework as well. Parents can work with their children to establish a threshold grade for homework (i.e. 88%, 93%, etc.). If grades are below that level, children know ahead of time that they will need to rework the homework assignment to ensure that they learn the material.
With this approach, redoing the homework isn’t punishment; it’s striving for learning and excellence.
When kids learn to interpret grades as feedback, and not a reflection of who they are or how smart they are, then how they feel about themselves won’t rise and fall based on the grades they receive.
About Renaye Thornborrow and Adventures in Wisdom Inc.
Renaye Thornborrow is leading a worldwide mission to bring life coaching to kids. Since 2013, her company, Adventures in Wisdom, has certified hundreds of coaches in over 30 countries, helping them create a business they love as a life coach for kids while empowering children around the world. For Renaye, motherhood was the catalyst for turning her lifelong passion for personal development into a comprehensive and effective story-based coaching curriculum to bring life coaching to kids. Life coaching is a game changer for children as they learn how to build confidence, resilience, and mindset skills for life; and it is a game changer for coaches as they increase their impact and income while doing their work in the world serving kids. To learn more, visit www.adventuresinwisdom.com, call 512-222-6659, or send email to [email protected]
